Standard BioTools (NASDAQ:LAB) Director Casdin Partners Master Fund, L Acquires 7,550,000 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 7,550,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was purchased at an average price of $1.30 per share, for a total transaction of $9,815,000.00. Following the acquisition, the director directly owned 71,750,000 shares in the company, valued at $93,275,000. This represents a 11.76% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Monday, November 24th, Casdin Partners Master Fund, L acquired 150,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.43 per share, with a total value of $214,500.00.
• On Thursday, November 20th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.30 per share, with a total value of $585,000.00.
• On Wednesday, November 19th, Casdin Partners Master Fund, L purchased 350,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.28 per share, for a total transaction of $448,000.00.
• On Tuesday, November 18th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.23 per share, for a total transaction of $338,250.00.
• On Monday, November 17th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.22 per share, with a total value of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.24 per share, for a total transaction of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.20 per share, for a total transaction of $540,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L purchased 375,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.19 per share, with a total value of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L purchased 300,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.20 per share, with a total value of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.17 per share, for a total transaction of $321,750.00.

Standard BioTools Stock Performance

LAB opened at $1.43 on Thursday. The stock has a market capitalization of $549.93 million, a PE ratio of -4.47 and a beta of 1.25. Standard BioTools Inc. has a one year low of $0.92 and a one year high of $2.25. The business’s 50 day moving average price is $1.29 and its 200 day moving average price is $1.24.

Institutional Trading of Standard BioTools

Several hedge funds have recently modified their holdings of LAB. Jump Financial LLC acquired a new position in Standard BioTools during the 1st quarter worth $26,000. Russell Investments Group Ltd. boosted its stake in shares of Standard BioTools by 2,989.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after buying an additional 24,211 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in shares of Standard BioTools by 115.6% during the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company’s stock worth $29,000 after buying an additional 14,541 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Standard BioTools by 103.6% during the third quarter. Federated Hermes Inc. now owns 28,545 shares of the company’s stock worth $37,000 after buying an additional 14,523 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Standard BioTools by 101.8% during the first quarter. CWM LLC now owns 29,705 shares of the company’s stock worth $32,000 after buying an additional 14,984 shares during the period. 53.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Cowen lowered Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Wall Street Zen cut shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Finally, TD Cowen reduced their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research note on Wednesday, November 5th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.